Dual roles of IL-18 in colitis through regulation of the function and quantity of goblet cells

Pu,Zhichen; Che,Yuan; Zhang,Weiwei; Sun,Hui; Meng,Tuo; Xie,Haitang; Cao,Lijuan; Hao,Haiping

doi:10.3892/ijmm.2019.4156

Dual roles of IL-18 in colitis through regulation of the function and quantity of goblet cells

Authors:
- Zhichen Pu
- Yuan Che
- Weiwei Zhang
- Hui Sun
- Tuo Meng
- Haitang Xie
- Lijuan Cao
- Haiping Hao
View Affiliations

Affiliations: State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China, Department of Pharmacy, Fourth People's Hospital of Maanshan, Maanshan, Anhui 243031, P.R. ChinaV, Department of Clinical Pharmacy, Yijishan Hospital of Wannan Medical College, Anhui Provincial Center for Drug Clinical Evaluation, Wuhu, Anhui 241001
Published online on: April 4, 2019 https://doi.org/10.3892/ijmm.2019.4156
Pages: 2291-2302
Copyright: © Pu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The main aim of the present study was to investigate the dual roles and mechanism of interleukin (IL)‑18 in dextran sulfate sodium (DSS)‑induced colitis. Firstly, meta‑analysis was used to explore whether the levels of IL‑18 were different in patients with colon cancer or inflammatory bowel disease. The results demonstrated that IL‑18 (rs187238, ‑137G/C) increased the incidence rate of colon cancer in patients, while IL‑18 (rs187238, ‑137G/C) decreased the incidence rate of ulcerative colitis or Crohn's disease in patients. Therefore, IL‑18 (rs187238, ‑137G/C) may have a dual function in colitis. Next, the functional role of IL‑18 in colitis was further investigated, by use of a DSS‑induced colitis mouse model. Pre‑treatment of the mice with IL‑18 increased body weight, augmented colon length, reduced inflammatory infiltration, promoted mucin (Muc)‑2 expression, increased the function and quantity of goblet cells and increased the mRNA levels of resistin‑like molecule (RELM) β and trefoil factor family (TFF) 3 in mice with DSS‑induced colitis, through the IL‑22/STAT3 pathway. By contrast, treatment with IL‑18 at later stages of the disease reduced body weight, decreased colon length, enhanced inflammatory infiltration and reduced Muc‑2 expression, decreased the function and quantity of goblet cells and inhibited the mRNA levels of RELMβ and TFF3 in mice with DSS‑induced colitis. In conclusion, IL‑18 served a dual function in colitis by regulating the function of goblet cells. The anti‑inflammatory effects of IL‑18 were observed in the early stage of colitis‑induced inflammation, while the pro‑inflammatory effects were observed in the later stages of the disease.

View Figures

View References

1	D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, et al: Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn's disease. Gastroenterology. 154:1343–1351e1. 2018. View Article : Google Scholar
2	Tan B, Li P, Lv H, Yang H, Li Y, Li J, Wang O and Qian JM: Treatment of vitamin D deficiency in Chinese inflammatory bowel disease patients: A prospective, randomized, open-label, pilot study. J Dig Dis. 19:215–224. 2018. View Article : Google Scholar : PubMed/NCBI
3	Ling XH, Yu X, Kong DJ, Hu CY, Hong Y and Yang XM: Treatment of inflammatory bowel disease with Chinese drugs administered by both oral intake and retention enema. Chin J Integr Med. 16:222–228. 2010. View Article : Google Scholar : PubMed/NCBI
4	Buckley JP, Kappelman MD, Allen JK, Van Meter SA and Cook SF: The burden of comedication among patients with inflammatory bowel disease. Inflamm Bowel Dis. 19:2725–2736. 2013. View Article : Google Scholar : PubMed/NCBI
5	Sun CM, Wu J, Zhang H, Shi G and Chen ZT: Circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity as well as inflammatory cyto-kines in patients with Crohn's disease. World J Gastroenterol. 23:7888–7898. 2017. View Article : Google Scholar : PubMed/NCBI
6	Maerten P, Shen C, Colpaert S, Liu Z, Bullens DA, van Assche G, Penninckx F, Geboes K, Vanham G, Rutgeerts P, et al: Involvement of interleukin 18 in Crohn's disease: Evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models. Clin Exp Immunol. 135:310–317. 2004. View Article : Google Scholar : PubMed/NCBI
7	Reuter BK and Pizarro TT: Commentary: The role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: Friend or foe. Eur J Immunol. 34:2347–2355. 2004. View Article : Google Scholar : PubMed/NCBI
8	Fang L, Pang Z, Shu W, Wu W, Sun M, Cong Y and Liu Z: Anti-TNF Therapy induces CD4⁺ T-cell production of IL-22 and promotes epithelial repairs in patients with Crohn's disease. Inflamm Bowel Dis. 24:1733–1744. 2018. View Article : Google Scholar : PubMed/NCBI
9	Yang GX, Sun Y, Tsuneyama K, Zhang W, Leung PS, He XS, Ansari AA, Bowlus C, Ridgway WM and Gershwin ME: Endogenous interleukin-22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II mice. Clin Exp Immunol. 185:154–164. 2016. View Article : Google Scholar : PubMed/NCBI
10	Li LJ, Gong C, Zhao MH and Feng BS: Role of interleukin-22 in inflammatory bowel disease. World J Gastroentero. 20:18177–18188. 2014. View Article : Google Scholar
11	Mizoguchi A: Healing of intestinal inflammation by IL-22. Inflamm Bowel Dis. 18:1777–1784. 2012. View Article : Google Scholar : PubMed/NCBI
12	Arj A, Razavizadeh M, Mohammadi H, Nikoueinejad H and Akbari H: The correlation between the numerical status of Th22 cells and serum level of IL-22 with severity of ulcerative colitis. Iran J Allergy Asthma Immuno. 17:78–84. 2018.
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔ^C T method. Methods. 25:402–408. 2001. View Article : Google Scholar
14	Nikiteas N, Yannopoulos A, Chatzitheofylaktou A and Tsigris C: Heterozygosity for interleukin-18-607 A/C polymorphism is associated with risk for colorectal cancer. Anticancer Res. 27:3849–3853. 2007.
15	Haghshenas MR, Hosseini SV, Mahmoudi M, Saberi-Firozi M, Farjadian S and Ghaderi A: IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol. 24:1119–1122. 2009. View Article : Google Scholar : PubMed/NCBI
16	Guo JY, Qin AQ, Li RK, Yang CM, Huang FD, Huang ZY and Guo HJ: Association of the IL-18 gene polymorphism with susceptibility to colorectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 15:400–403. 2012.In Chinese. PubMed/NCBI
17	Ben Aleya W, Sfar I, Habibi I, Mouelhi L, Aouadi H, Makhlouf M, Ayed-Jendoubi S, Najjar T, Ben Abdallah T, Ayed K, et al: Interleukin-18 gene polymorphisms in tunisian patients with inflammatory bowel disease. Digestion. 83:269–274. 2011. View Article : Google Scholar : PubMed/NCBI
18	Takagawa T, Tamura K, Takeda N, Tomita T, Ohda Y, Fukunaga K, Hida N, Ohnishi K, Hori K, Kosaka T, et al: Association between IL-18 gene promoter polymorphisms and inflammatory bowel disease in a Japanese population. Inflamm Bowel Dis. 11:1038–1043. 2005. View Article : Google Scholar : PubMed/NCBI
19	Aizawa Y, Sutoh S, Matsuoka M, Negishi M, Torii A, Miyakawa Y, Sugisaka H, Nakamura M and Toda G: Association of interleukin-18 gene single-nucleotide polymorphisms with susceptibility to inflammatory bowel disease. Tissue Antigens. 65:88–92. 2005. View Article : Google Scholar : PubMed/NCBI
20	Haas SL, Andreas Koch W, Schreiber S, Reinhard I, Koyama N, Singer MV and Böcker U: -137 (G/C) IL-18 promoter polymorphism in patients with inflammatory bowel disease. Scand J Gastroentero. 40:1438–1443. 2005. View Article : Google Scholar
21	Dong YB and Chen GY: Association analysis of IL-18 gene polymorphisms and ulcerative colitis in Chinese Han population. Chin J Clin Gastroenterol. 21:21–22. 2009.In Chinese.
22	Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J, Ydegaard Turino S, Brodersen JB, Rashid S, Kaiser Rasmussen B, et al: Polymorphisms in the toll-like receptor and the IL-23/IL-17 pathways were associated with susceptibility to inflammatory bowel disease in a danish cohort. PLoS One. 10:e01453022015. View Article : Google Scholar : PubMed/NCBI
23	Dong YB, Bo WL, Feng XB and Chen GY: Association between single nucleotide polymorphismin of interleukin-18 gene and ulcerative colitis in Han population of Shanghai. World Chin J Digestology. 16:2785–2787. 2008.In Chinese. View Article : Google Scholar
24	Motamed F, Famouri F, Najafi M, Moazzami K, Farahmand F, Khodadad A, Fallahi GH, Khatami GR and Rezaei N: Response to induction therapy in a pediatric population of inflammatory bowel disease. Z Gastroenterol. 48:748–752. 2010. View Article : Google Scholar : PubMed/NCBI
25	Wiercinska-Drapalo A, Flisiak R, Jaroszewicz J and Prokopowicz D: Plasma interleukin-18 reflects severity of ulcerative colitis. World J Gastroenterol. 11:605–608. 2005. View Article : Google Scholar : PubMed/NCBI
26	Striz I: Cytokines of the IL-1 family: Recognized targets in chronic inflammation underrated in organ transplantations. Clin Sci. 131:2241–2256. 2017. View Article : Google Scholar : PubMed/NCBI
27	Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Wetzke M, et al: Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22- expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 63:567–577. 2014. View Article : Google Scholar
28	Yu LZ, Wang HY, Yang SP, Yuan ZP, Xu FY, Sun C and Shi RH: Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis. World J Gastroenterol. 19:2638–2649. 2013. View Article : Google Scholar : PubMed/NCBI
29	Ratsimandresy RA, Indramohan M, Dorfleutner A and Stehlik C: The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway. Cell Mol Immunol. 14:127–142. 2017. View Article : Google Scholar :
30	Turner JE, Stockinger B and Helmby H: IL-22 mediates goblet cell hyperplasia and worm expulsion in intestinal helminth infection. PLoS Pathog. 9:e10036982013. View Article : Google Scholar : PubMed/NCBI
31	Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, Blumberg RS, Xavier RJ and Mizoguchi A: IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 118:534–544. 2008.PubMed/NCBI